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Glucocorticoid compounds modify 
Smoothened localization and 
Hedgehog pathway activity
Wang et al., Chem Biol 2012; 19: 972–982; doi:10.1016/j.chembiol.2012.06.012
The primary cilium works as a cellular antenna that captures 
mechanical and chemical stimuli from the extracellular environ-
ment. In renal tubular cells, cilium orientation to the tubular lumen 
senses the fluid flow; in bone, the cilium responds to compression 
forces transmitted by the extracellular matrix. Disruptions of the 
primary cilium have been associated with polycystic kidney disease 
and ciliopathies, which comprise a growing list of syndromes that 
can involve cystic kidneys, obesity, mental retardation, blindness, 
and various developmental malformations, caused by mutations 
of proteins localized to the cilium and its basal body. Changes in 
ciliary function have also been proposed to support cancer progres-
sion, and the extensive signaling between cilia and the extracellular 
matrix seems to associate cilium defect with fibrosis in multiple 
contexts. In parallel, genetic studies in mice have described Hedge-
hog as a major signaling pathway in the cilium. A crucial role in 
the Hedgehog pathway is played by Smoothened (Smo), a protein 
that translocates to the primary cilium upon Hedgehog activation, 
and this transition is critical for the response to Hedgehog ligands. 
Wang and collaborators screened a large chemical library and found 
that, of drugs capable of inducing Smo accumulation at the cilium, 
most are naturally occurring or synthetic glucocorticoids, several 
of which are widely used as anti-inflammatory agents.
The authors demonstrate that the effect is specific and dependent 
on direct interaction between the glucocorticoid and Smo. Smo 
accumulation does not directly activate the Hedgehog pathway, 
but it confers hypersensitivity to Hedgehog stimulation, and the 
effect persists after glucocorticoid withdrawal. Although most 
glucocorticoids induce Smo accumulation, the authors also find 
that two small molecules sharing the core glucocorticoid scaffold, 
namely budesonide and ciclesonide, are instead inhibitors of Smo 
translocation to the cilium.
These novel mechanisms of glucocorticoid action have the 
potential to ameliorate the use of these drugs in numerous clinical 
settings and, thus, need to be addressed by further studies.
Maria Pia Rastaldi
Direct regulation of blood 
pressure by smooth muscle cell 
mineralocorticoid receptors
McCurley et al., Nat Med 2012; 18: 1429–1435; doi:10.1038/nm.2891
The role of the renin–angiotensin–aldosterone system (RAAS) 
in blood pressure regulation has been the subject of innumer-
able studies. Though activation of the mineralocorticoid receptor 
(MR) in renal tubular cells with a subsequent increase in sodium 
reabsorption is clearly an important mechanism by which 
mineral ocorticoids increase blood pressure, animal models and 
clinical studies suggest that MR activation in nonrenal cells may 
also affect blood pressure. Global MR knockout mice die from salt 
wasting in the perinatal period, but tubule-specific MR knockout 
mice survive unless challenged with a low-salt diet. Since vascular 
smooth muscle cells (SMCs) express the MR, McCurley and co-
workers tested the hypothesis that SMC-specific knockout of the 
MR would decrease blood pressure. They used Cre-lox technology 
to generate tamoxifen-inducible SMC-specific MR knockout mice. 
SMC-MR-deficient mice had lower blood pressure (Figure) but 
no differences in urinary sodium concentration or vascular struc-
ture when compared with control mice. Interestingly, differences 
between SMC-MR-deficient mice and controls increased with age. 
Mesenteric arteries from aged (9-month-old) SMC-MR-deficient 
mice had increased responsiveness to vasoconstrictors compared 
with controls, but the difference between 3-month-old SMC-MR-
deficient mice and age-matched controls was minimal. To deter-
mine the mechanism for reduced blood pressure and vasopressor 
response in aged SMC-MR-deficient mice, the authors studied 
potassium and calcium channel expression and function in SMCs. 
Expression of the L-type calcium channel Cav1.2 was decreased 
in SMC-MR-deficient mesenteric vessels, and SMCs from these 
vessels were less sensitive to the L-type calcium channel agonist 
BayK8644, suggesting that lower levels of this channel may, in 
part, explain the lower blood pressure and vasopressor response 
in SMC-MR-deficient mice. Finally, since RAAS signaling is 
enhanced in aging blood vessels, the authors studied whether 
aged SMC-MR-deficient mice have decreased sensitivity to angio-
tensin II. These mice had a markedly attenuated increase in blood 
pressure, mesenteric vasoconstriction, and carotid superoxide 
production after response to angiotensin II infusion.
Although additional studies will need to definitely establish 
whether SMC-MR activation influences sodium balance, these 
data strongly suggest that MR-induced arterial vasoconstriction 
is an important contributor to the effect of mineralocorticoids 
on blood pressure.
Michael Ross
SMC-MR-deficient (Cre+) mice had decreased mean 24-hour blood 
pressure compared with control (Cre–) mice. 
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Lysophosphatidic acid increases 
proximal tubule cell secretion of 
profibrotic cytokines PDGF-B and 
CTGF through LPA2- and Gaq-
mediated Rho and avb6 integrin-
dependent activation of TGF-b
Geng et al., Am J Pathol 2012; 181: 1236–1249; doi:10.1016/ 
j.ajpath.2012.06.035
There is a widespread and growing acceptance that acute kid-
ney injury (AKI) leads to CKD and ESRD, necessitating a 
better understanding of the pathogenesis by which AKI leads 
to renal fibrosis and progressive renal failure. How tubule 
injury leads to fibrosis is a central question that remains 
unresolved. Geng and co-workers elegantly describe the 
relationship between transforming growth factor-b (TGF-
b) signaling mechanisms linking upstream initiating factors 
with downstream effectors (Figure). In this study, they dem-
onstrated in vivo that, following ischemia–reperfusion injury, 
proximal tubules that are incompletely repaired express acti-
vated TGF-b and downstream mediators of fibrosis such as 
platelet-derived growth factor-B (PDGF-B) and connective 
tissue growth factor (CTGF). TGF-b was expressed early and 
increased progressively, leading to tubulointerstitial fibrosis. 
Lysophosphatidic acid (LPA), a small ubiquitous phospho-
lipid, acts as an extracellular signal molecule by binding 
to at least five known G protein–coupled receptors: LPA1–
LPA5. Aberrant LPA signaling is implicated in numerous 
pathologies, including cancer and heart disease as well as kid-
ney injury and fibrosis. The increase in proximal tubule TGF-b 
occurred along with LPA2, a6 integrin proteins, PDGF-B, and 
CTGF. In cultured proximal tubule cells, an LPA1 and LPA3 
antagonist did not block TGF-b activation; however, short 
hairpin RNA specific for LPA2 did block TGF-b activation, 
suggesting that LPA2 was the major receptor involved in 
activation of TGF-b.
These results shed new light on the mechanisms of activation 
of TGF-b by LPA2, linking this pathway to kidney fibrosis. 
Additional studies are necessary to define the role of LPA 
receptor subtypes in kidney fibrosis, and translation to human 
disease awaits the development and testing of more selective 
and potent pharmacological agents for LPA receptors.
Mark Okusa
Stroke and bleeding in atrial 
fibrillation with chronic kidney 
disease
Olesen et al., N Engl J Med 2012; 367: 625–635; doi:10.1056/ 
NEJMoa1105594
The risk of stroke from atrial fibrillation in patients with 
chronic kidney disease (CKD) and end-stage renal disease 
(ESRD) and the effect of antithrombotic therapy in CKD 
patients are not well studied. Olesen et al. used Danish 
national registries to identify 132,372 patients discharged 
with a diagnosis of atrial fibrillation, of whom 2.7% had CKD 
and 0.7% had ESRD. Patients with CKD had an increased 
risk of stroke or systemic thromboembolism (hazard ratio, 
1.49; 95% con fidence interval (CI), 1.38–1.59), as did those 
with ESRD (hazard ratio, 1.83; 95% CI, 1.57–2.14). When all 
patients with renal disease were compared with those who 
had no renal disease, warfarin decreased the risk of stroke 
or systemic thrombo embolism (hazard ratio, 0.76; 95% CI, 
0.64–0.91), as did warfarin plus aspirin (hazard ratio, 0.74; 95% 
CI, 0.56–0.98). Aspirin was associated with an increased risk of 
stroke or systemic thromboembolism. The risk of bleeding was 
increased among patients with CKD or ESRD and was further 
increased with warfarin, aspirin, or both.
Thus, the net clinical effect of warfarin treatment requires 
careful assessment in patients with CKD. This observational 
study did not provide guidance on how optimally to manage 
these patients and should be evaluated in a clinical trial.
Jai Radhakrishnan
Fourteen days after ischemia–reperfusion, there was stimulation 
of TGF-b signaling inducing profibrotic peptide in renal proximal 
tubules.  Shown  are vimentin-positive tubules (green),  nuclear 
localization of Smad2 proteins (red) and nuclei (DAPI, blue). DAPI,  
4’, 6-diamidino-2-phenylindole; IRI, ischemia–reperfusion injury.
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